Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pharmalink Initiates Phase IIb Trial with Nefecon®

Published: Friday, December 21, 2012
Last Updated: Friday, December 21, 2012
Bookmark and Share
Pharmalink expects to announce top line results in the first half of 2015.

Pharmalink AB has announced that it has initiated a Phase IIb study with Nefecon® (Nefigan) in patients with primary IgA nephropathy at risk of developing end-stage renal disease.

Nefecon is an enteric formulation of a locally acting corticosteroid that down-regulates the inflammatory process in the kidneys through suppression of the gastrointestinal immune system.

The study is a multi-center, randomized, double-blinded placebo controlled study to evaluate the efficacy and safety of two different doses of Nefecon in 90 primary IgA nephropathy patients at risk of end-stage renal disease.

The first patient was recently enrolled in the clinical trial, which will be conducted at approximately 50 participating centers across 10 European countries.

The primary objective will be to investigate whether patients on Nefecon have a larger mean reduction in proteinuria compared to patients on placebo. Pharmalink expects to announce top line results in the first half of 2015.

Nefecon showed positive results in an open-labelled Phase IIa trial evaluating safety and efficacy with 16 patients at trial centers in Sweden.

The final results of the study demonstrated a significant and clinically meaningful effect in the primary endpoint: reduction in proteinuria.

Significant results were also seen in secondary endpoints: reduction of serum creatinine and increase in glomerular filtration rates. Furthermore, Nefecon was well tolerated with few or no-drug related side effects.

IgA nephropathy is an orphan condition and Nefecon is aimed at providing patients with IgA nephropathy a disease modifying medication.

Alex Mercer, Clinical Development Director at Pharmalink, said: “IgA nephropathy is a disease with a high unmet medical need and no approved treatments available on the market today. Progression to renal failure has a terrible impact on patients’ quality of life and is a high burden to health care systems. Pharmalink hopes to bring a new medicine to patients for early treatment, halting disease progression and further loss of renal function. We look forward to confirming the highly promising results we have seen so far with Nefecon and to advancing the product in this pivotal phase IIb trial.”

Nefecon® is a patented invention by Professors Bengt Fellström and Roger Hällgren at Uppsala University (Sweden) and was acquired by Pharmalink in 2004.

Nefecon® is delivered using the proprietary TARGIT® drug delivery technology which enables the localized delivery of drugs to the lower small intestine or colonic regions of the gastrointestinal tract.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pharmalink AB Strengthens Senior Management Team
Dr. Heather Cook appointed director of regulatory affairs and Marek Poszepczynski as director of business development.
Thursday, February 21, 2013
Pharmalink Enters Manufacturing Agreement for Nefecon®
Company has entered into a contract with Patheon.
Thursday, November 01, 2012
Pharmalink AB Raises SEK 35 Million through Share Issue
New funds used to further advance Nefecon® and Busulipo™.
Friday, January 06, 2012
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!